Sign up
Pharma Capital

Does US court ruling spell the end for Indivior?

Proactive Investors editor Ian Lyall discusses the patent infringement case that effectively gives the green light to a company called Dr Reddy’s to produce a copycat version of Indivior PLC's (LON:INDV) heroin subsitute drug Suboxone at a fraction of the current price.

The immediate reaction on the markets was one of horror as 40%, or £1.1bn was wiped from Indivior’s value.

 

View full INDV profile

Indivior Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.